On April 19, 2025, Zelgen Pharmaceuticals (688266.SH) released its 2024 annual report.

The company's total operating income was 533 million yuan. The net profit attributable to the parent company was -138 million yuan. The net cash inflow from operating activities was 38.2045 million yuan.

The company's latest asset-liability ratio was 58.31%, an increase of 15.28 percentage points over the same period last year.

The company's latest gross profit margin was 93.06%, an increase of 0.62 percentage points over the gross profit margin of the same period last year. The latest ROE is -10.99%.

The company's diluted earnings per share were -0.52 yuan.

The company's latest total asset turnover ratio is 0.18 times. The latest inventory turnover rate was 0.25 times, a decrease of 0.03 times from the same period last year, and a decrease of 9.52% from the same period last year.

The number of shareholders of the company is 8,347, and the number of shares held by the top ten shareholders is 122 million shares, accounting for 45.91% of the total share capital

The company's total R&D investment was 388 million yuan, ranking fourth in the performance of the same period in the past five years, a decrease of 108 million yuan compared with the total R&D investment in the same reporting period last year, and a decrease of 21.83% compared with the same period last year. The latest R&D investment accounted for 72.80%, ranking 5th in the same period in the past five years, a decrease of 55.64 percentage points from the same period last year.